Micron to Select Athinia™ for Pioneering Data Collaboration
A long-term, strategic, enterprise-level technology collaboration aims to further increase production efficiencies and reduce costs for Micron and its suppliers CAMBRIDGE, Mass., July 19, 2022 /PRNewswire/ -- Today, Athinia™ announced that Micron Technology, Inc. (Nasdaq: MU), a global leader in...
ERBITUX® Approved for First-line Use in China in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
Approval is for ERBITUX® in combination with platinum-based therapy with fluorouracil for the first-line treatment of R/M SCCHN Pivotal Phase III study shows significant improvements with ERBITUX® in combination with platinum-based therapy with fluorouracil in response rate, disease progression ...
Merck Announces Orphan Drug Designation for Investigational Therapy Tepotinib in Patients with NSCLC Harboring MET Gene Alterations
- Japanese Ministry of Health, Labour and Welfare grants orphan drug designation for diseases that affect fewer than 50,000 patients inJapan, and for which significant unmet medical need exists - MET exon 14 (METex14) skipping alterations and MET amplifications are present in 3-5% of non-small c...
Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine
Not intended for US, Canada and UK-based media DARMSTADT, Germany and NEW YORK, Feb. 18, 2019 /PRNewswire/ -- * JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression * US FDA has granted Priority Rev...
